Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

2(33.3%)

Phase 4

2(33.3%)

Early Phase 1

1(16.7%)

Phase 3

1(16.7%)

6Total

Phase 2(2)

Phase 4(2)

Early Phase 1(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06721871Phase 2Active Not Recruiting

Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID)

Role: lead

NCT03898856Phase 4Completed

Yield of Diagnostic Tests and Effects of Crofelemer for Chronic Idiopathic Diarrhea In Non-HIV Patients

Role: collaborator

NCT06326645Early Phase 1Recruiting

Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome

Role: collaborator

NCT04538625Phase 3Completed

Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy

Role: lead

NCT02910219Phase 2Completed

Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients

Role: collaborator

NCT04192487Phase 4Completed

Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in HIV+ Patients With Non-Infectious Diarrhea

Role: lead

All 6 trials loaded